1921
Volume 99, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

At the end phase of the Global Programme to Eliminate Lymphatic Filariasis, antibody testing may have a role in decision-making for bancroftian filariasis–endemic areas. This study evaluated the diagnostic performance of BLF Rapid, a prototype immunochromatographic IgG4-based test using SXP recombinant protein, for detection of bancroftian filariasis. The test was evaluated using 258 serum samples, comprising 96 samples tested at Universiti Sains Malaysia (in-house) and 162 samples tested independently at three international laboratories in the USA and India, and two laboratories in Malaysia. The independent testing involved 99 samples from microfilaria or antigen positive individuals and 63 samples from people who were healthy or had other infections. The in-house evaluation showed 100% diagnostic sensitivity and specificity. The independent evaluations showed a diagnostic sensitivity of 84–100% and 100% specificity (excluding non-lymphatic filarial infections). BLF Rapid has potential as a surveillance diagnostic tool to make “Transmission Assessment Survey”–stopping decisions and conduct post-elimination surveillance.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.18-0566
2018-10-22
2020-09-21
Loading full text...

Full text loading...

/deliver/fulltext/14761645/99/6/tpmd180566.html?itemId=/content/journals/10.4269/ajtmh.18-0566&mimeType=html&fmt=ahah

References

  1. WHO, 2017. Global programme to eliminate lymphatic filariasis: progress report, 2016. Wkly Epidemiol Rec 92: 594607.
    [Google Scholar]
  2. Shenoy RK, 2008. Clinical and pathological aspects of filarial lymphedema and its management. Korean J Parasitol 46: 119125.
    [Google Scholar]
  3. GBD 2016 DALYs and HALE Collaborators, 2017. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2013; 2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390: 12601344.
    [Google Scholar]
  4. World Health Organization, 2011. Lymphatic Filariasis: Monitoring and Epidemiological Assessment of Mass Drug Administration: A Manual for National Elimination Programmes. Geneva, Switzerland: WHO/HTM/NTD/PCT/2011.4.
    [Google Scholar]
  5. Kwan-Lim GE, Forsyth KP, Maizels RM, 1990. Filarial-specific IgG4 response correlates with active Wuchereria bancrofti infection. J Immunol 145: 42984305.
    [Google Scholar]
  6. Dewi RM, Tuti S, Ganefa S, Anwar C, Larasati R, Ariyanti E, Herjati H, Brady M, 2015. Brugia rapid antibody responses in communities of Indonesia in relation to the results of 'transmission assessment surveys' (TAS) for the lymphatic filariasis elimination program. Parasit Vectors 8: 499.
    [Google Scholar]
  7. Noordin R, Mohd Zain SN, Yunus MH, Sahimin N, 2017. Seroprevalence of lymphatic filariasis among migrant workers in Peninsular Malaysia. Trans R Soc Trop Med Hyg 111: 370372.
    [Google Scholar]
  8. Vythilingam I, 2012. Plasmodium knowlesi and Wuchereria bancrofti: their vectors and challenges for the future. Front Physiol 3: 115.
    [Google Scholar]
  9. Ismail MM, Weil GJ, Jayasinghe KS, Premaratne UN, Abeyewickreme W, Rajaratnam HN, Sheriff MH, Perera CS, Dissanaike AS, 1996. Prolonged clearance of microfilaraemia in patients with bancroftian filariasis after multiple high doses of ivermectin or diethylcarbamazine. Trans R Soc Trop Med Hyg 90: 684688.
    [Google Scholar]
  10. Won KY, Sambou S, Barry A, Robinson K, Jaye M, Sanneh B, Sanyang A, Gass K, Lammie PJ, Rebollo M, 2018. Use of antibody tools to provide serologic evidence of elimination of lymphatic filariasis in the Gambia. Am J Trop Med Hyg 98: 1520.
    [Google Scholar]
  11. Gass K et al., 2012. A multicenter evaluation of diagnostic tools to define endpoints for programs to eliminate bancroftian filariasis. PLoS Negl Trop Dis 6: e1479.
    [Google Scholar]
  12. Washington CH et al., 2004. Spatial clustering of filarial transmission before and after a mass drug administration in a setting of low infection prevalence. Filaria J 3: 3.
    [Google Scholar]
  13. Won KY et al., 2018. Comparison of antigen and antibody responses in repeat lymphatic filariasis transmission assessment surveys in American Samoa. PLoS Negl Trop Dis 12: e0006347.
    [Google Scholar]
  14. Weil GJ, Ramzy RM, 2007. Diagnostic tools for filariasis elimination programs. Trends Parasitol 23: 7882.
    [Google Scholar]
  15. Ramzy RM, El Setouhy M, Helmy H, Ahmed ES, Abd Elaziz KM, Farid HA, Shannon WD, Weil GJ, 2006. Effect of yearly mass drug administration with diethylcarbamazine and albendazole on bancroftian filariasis in Egypt: a comprehensive assessment. Lancet 367: 992999.
    [Google Scholar]
  16. Steel C, Golden A, Kubofcik J, LaRue N, de los Santos T, Domingo GJ, Nutman TB, 2013. Rapid Wuchereria bancrofti-specific antigen Wb123-based IgG4 immunoassays as tools for surveillance following mass drug administration programs on lymphatic filariasis. Clin Vaccine Immunol 20: 11551161.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.18-0566
Loading
/content/journals/10.4269/ajtmh.18-0566
Loading

Data & Media loading...

  • Received : 10 Jul 2018
  • Accepted : 11 Sep 2018
  • Published online : 22 Oct 2018
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error